ReviewCurrent hypertension reports2012
MicroRNAs in hypertension: mechanisms and therapeutic targets.
Review in Current hypertension reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy: a meta-analysis of randomized controlled trials.Journal of human hypertension · 2013Pooled it
- Exercise training improves endothelial function in resistance arteries of young prehypertensives.Journal of human hypertension · 2014Trial
- Role of miR-155 and miR-103 in Oxidative Stress in Cardiovascular Disease: A Narrative Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- Identification of miRNA biomarkers for essential hypertension in small samples based on MPGAM.Scientific reports · 2025Article
- Comorbidity of hypertension and lung cancer: interplay of genetics and environment.Discover oncology · 2025Review
- Evaluation of miRNA Profile and Its Relationship with Metabolic Disorders in Obese and Pre-Obese Patients.Current issues in molecular biology · 2025Article
- Association between Hypertension with and without Left Ventricular Hypertrophy and the Expression of a Panel of microRNAs in an Iranian Population.Research in heart yield and translational medicine · 2025Article
- Kidney Programming and Hypertension: Linking Prenatal Development to Adulthood.International journal of molecular sciences · 2024Review
- The pharmaco-epigenetics of hypertension: a focus on microRNA.Molecular and cellular biochemistry · 2024Review
- Investigation of Antihypertensive Properties of Chios Mastic via Monitoring microRNA-21 Expression Levels in the Plasma of Well-Controlled Hypertensive Patients.Non-coding RNA · 2024Article
- Circulating microRNA Biomarkers of Thiazide Response in Hypertension.Journal of the American Heart Association · 2024Article
- A Machine Learning Model Based on microRNAs for the Diagnosis of Essential Hypertension.Non-coding RNA · 2023Article
- miR-146a, miR-221, and miR-155 are Involved in Inflammatory Immune Response in Severe COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2022Article
- Epigenetic Mechanisms Involved in Inflammaging-Associated Hypertension.Current hypertension reports · 2022Review
- Article
- Article
- ncRNAs and polyphenols: new therapeutic strategies for hypertension.RNA biology · 2022Article
- MicroRNA-146: Biomarker and Mediator of Cardiovascular Disease.Disease markers · 2022Review
- Exosomes as Intercellular Messengers in Hypertension.International journal of molecular sciences · 2021Review
- Long Non-Coding RNAs in Cardiovascular Diseases: Potential Function as Biomarkers and Therapeutic Targets of Exercise Training.Non-coding RNA · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a complex, multifactorial disease, and its development is determined by a combination of genetic susceptibility and environmental factors. Several mechanisms have been implicated in the pathogenesis of hypertension: increased activity of the sympathetic nervous system, overactivation of the renin-angiotensin aldosterone system (RAAS), dysfunction of vascular endothelium, impaired platelet function, thrombogenesis, vascular smooth muscle and cardiac hypertrophy, and altered angiogenesis. MicroRNAs are short, noncoding nucleotides regulating target messenger RNAs at the post-transcriptional level. MicroRNAs are involved in virtually all biologic processes, including cellular proliferation, apoptosis, and differentiation. Thus, microRNA deregulation often results in impaired cellular function and disease development, so microRNAs have potential therapeutic relevance. Many aspects of the development of essential hypertension at the molecular level are still unknown. The elucidation of these processes regulated by microRNAs and the identification of novel microRNA targets in the pathogenesis of hypertension is a highly valuable and exciting strategy that may eventually led to the development of novel treatment approaches for hypertension. This article reviews the potential role of microRNAs in the mechanisms associated with the development and consequences of hypertension and discusses advances in microRNA-based approaches that may be important in treating hypertension.
Indexed as
Identifiers
22052337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.